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Effect of Dental Scaling and Root Planing on Serum Inflammatory Markers in
Patients with Coronary Heart Disease: A Systematic Review
Abstract
Background: Coronary heart disease is a common manifestation of atherosclerosis. Various
inflammatory markers including C-reactive protein, tumor necrosis factor-alpha, interleukin-6, and
fibrinogen play role in the development of atherosclerosis. Periodontitis is the inflammation of teeth
supporting structures initiated by bacteria of the oral biofilm. Several studies have shown that
periodontitis is associated with increased levels of serum inflammatory markers involved in
atherosclerosis. Recently, there is an increasing number of trials investigating the effect of scaling and
root planing on reducing level of systemic inflammation between periodontal maintenance visits in
patients with coronary heart disease to decrease the inflammatory burden in this targeted population and
the risk of secondary cardiovascular event. Objective: The aim of this study is to conduct a systematic
review to investigate the effect of dental scaling and root planning on reducing the serum levels of
inflammatory markers in patients with stable coronary heart disease. Method: Electronic searches were
conducted in PubMed, Scopus, Cochrane Library, ClinicalTrials.gov, World Health Organization (WHO)
International Trials Registry Platform, and Google Scholar beta to identify randomized controlled trial
evaluated the effect of scaling and root planing on the level of serum inflammatory markers in patients
with stable coronary heart disease to those who have coronary heart disease but received no treatment or
simple oral hygiene measures only. Results: A total of 358 studies were initially identified from the search;
4 studies met the inclusion criteria and were selected for this systematic review. All of the included
studies have considered C-reactive protein as a main outcome measure. Only one study considered
evaluating the effect on fibrinogen, another study on interleukin-6, and two studies on tumor necrosis
factor-alpha. In general, the results of the included randomized controlled trials appear to support the
effectiveness of scaling and root planing in reducing serum levels of inflammatory markers. However,
most of the studies involved small sample sizes except for one study, and there was inconsistency
between the studies in the time considered for assessing the change in the level of serum inflammatory
markers. Conclusion: There is a low evidence from the current literature supporting the effect of scaling
and root planing in reducing systemic inflammatory markers including C-reactive protein, tumor necrosis
factor-alpha, interleukin-6, and fibrinogen in patients with stable coronary heart disease. Future research
should include observational studies to assess the effect of scaling and root planing in reducing the
inflammatory burden in this targeted population and the risk of secondary cardiovascular event.
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Background: Coronary heart disease is a common manifestation of
atherosclerosis. Various inflammatory markers including C-reactive protein (CRP),
tumor necrosis factor- (TNF-), interleukin-6 (IL-6), and fibrinogen play role in the
development of atherosclerosis. Periodontitis is the inflammation of teeth
supporting structures initiated by bacteria of the oral biofilm. Several studies have
shown that periodontitis is associated with increased levels of serum inflammatory
markers involved in atherosclerosis. Recently, there is an increasing number of
trials investigating the effect of scaling and root planing on reducing level of
systemic inflammation between periodontal maintenance visits in patients with
coronary heart disease to decrease the inflammatory burden in this targeted
population and the risk of secondary cardiovascular event. Objective: The aim of
this study is to conduct a systematic review to investigate the effect of dental
scaling and root planning on reducing the serum levels of inflammatory markers in
patients with stable coronary heart disease. Method: Electronic searches were
conducted in PubMed, Scopus, Cochrane Library, ClinicalTrials.gov, World Health
Organization (WHO) International Trials Registry Platform, and Google Scholar
beta to identify randomized controlled trial evaluated the effect of scaling and root
planing on the level of serum inflammatory markers in patients with stable coronary
heart disease to those who have coronary heart disease but received no treatment
or simple oral hygiene measures only. Results: A total of 358 studies were initially
identified from the search; 4 studies met the inclusion criteria and were selected
for this systematic review. All of the included studies have considered C-reactive
protein (CRP) as a main outcome measure. Only one study considered evaluating
the effect on fibrinogen, another study on interleukin-6 (IL-6), and two studies on
tumor necrosis factor- (TNF-). In general, the results of the included randomized
controlled trials appear to support the effectiveness of scaling and root planing in
reducing serum levels of inflammatory markers. However, most of the studies
involved small sample sizes except for one study, and there was inconsistency
between the studies in the time considered for assessing the change in the level
of serum inflammatory markers. Conclusion: There is a low evidence from the
current literature supporting the effect of scaling and root planing in reducing
systemic inflammatory markers including C-reactive protein (CRP), tumor necrosis
factor- (TNF-), interleukin-6 (IL-6), and fibrinogen in patients with stable
coronary heart disease. Future research should include observational studies to
assess the effect of scaling and root planing in reducing the inflammatory burden
in this targeted population and the risk of secondary cardiovascular event.
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Effect of Dental Scaling and Root Planing on Serum
Inflammatory Markers in Patients with Coronary Heart
Disease: A Systematic Review

Background:
Coronary artery disease is the most common type of cardiovascular disease
affecting 16.5 million Americans (Benjamin et al, 2017). Coronary heart disease is
a common manifestation of atherosclerosis. Inflammation plays a pivotal role in the
development of atherosclerosis and the acute activation of the vascular wall with
consequent local thrombosis and vasoconstriction (Liuzzo, 2001). Various
inflammatory markers express different aspects of the inflammatory processes that
contribute to atherosclerosis (Ikonomidis et al, 2012). A decently studied serum
inflammatory marker is the C-reactive protein. C-reactive protein is a non-specific
highly sensitive systemic marker of inflammation and a predictor of incident
coronary heart disease (Koenig et al, 1999). A cut-off level of high sensitivity Creactive protein (hs-CRP) of 2 mg/L seems to discriminate high from low risk
patients with stable or unstable coronary disease or even apparently healthy
individuals for short and long-term prognosis of cardiovascular event (Zakynthinos
et al, 2009). Plasma fibrinogen have also been associated with atherosclerosis
progression in patients with stable coronary heart disease (Danesh et al, 1998;
Green et al, 2009; Shojaie et al, 2009). Moreover, Interleukin-6 plasma level could
reflect the extent of inflammatory reactions in atherosclerotic vessels and improve
the prediction of coronary heart disease risk (Luc et al, 2003). Recent large trial
demonstrated that Interleukin-6 was independently associated with the risk of
major coronary events in patients with stable coronary heart disease and may be
a potential future target for the treatment of stable coronary heart disease (Held et
al, 2017). During the past years, many efforts have been made to identify different
risk factors for coronary heart disease and their contribution to systemic
inflammation in order to offer targets for therapeutic and preventive interventions.
Mattila et al. (1989) conducted the first two case-control studies to examine the
role of chronic dental infections including periodontitis as risk factors for coronary
heart disease. Periodontitis is a chronic inflammation of teeth supporting
structures. It involves a complex immune/inflammatory cascade that is initiated
by the bacteria of the oral biofilm that forms naturally on the teeth (Cekici et al,
2000). The association between coronary heart disease and periodontitis has
3

been investigated by a significant body of evidence. A meta-analysis indicates
that both the prevalence and incidence of coronary heart disease are significantly
increased in periodontitis (Bahekar et al, 2007). Another systematic review and
meta-analysis identifies periodontal disease as a risk factor for coronary heart
disease that is independent of traditional coronary heart disease risk factors
(Humphrey at al, 2008). Recent systematic review indicates the association
between periodontitis and atherosclerosis, with elevated levels of inflammatory
markers, mainly C-reactive protein and IL-6 (Almeida et al, 2017).
The proposed mechanism that links periodontitis with coronary heart disease
is that the immune response in periodontitis affects systemic inflammatory burden
by increasing the release of serum markers of inflammation. Several studies have
shown that periodontitis is associated with increased levels of serum inflammatory
markers involved in atherosclerosis. Loos at al. (2000) found higher serum
concentrations of C-reactive protein, IL-6 and neutrophils in patients with
generalized and localized periodontitis than in controls. A Case-control study
showed an increased plasma concentration of risk markers for atherosclerosis
such as C-reactive protein, fibrinogen and IL-18, particularly in patients with severe
periodontitis (Buhlin, et al, 2009). Another study demonstrated that chronic
periodontitis results in higher serum concentrations of C-reactive protein, IL-6, total
leukocyte count and neutrophil. They found that patients in both chronic
generalized and chronic localized periodontitis have higher mean CRP levels than
in control group and that CRP level in the chronic generalized periodontitis group
was statistically significant when compared to the control group (Gani et al, 2012).

Interventional studies showed that periodontal therapy can reduce systemic
inflammation and level of serum inflammatory markers mainly C-reactive protein
in otherwise healthy subjects (Caula et al, 2014; Leite et al, 2014). Recently, there
is an increasing number of trials investigating the effect of mechanical non-surgical
periodontal therapy in reducing levels of serum inflammatory markers in patients
with coronary heart disease. The first prospective study to demonstrate the
presence of higher circulating levels of the proinflammatory cytokines MCSF, IL-6,
and IL-1b levels in patients with chronic stable angina compared with healthy
controls, also showed that aspirin can reduce cytokines and CRP levels which may
explain parts of its therapeutic action (Ikonomidis et al, 1999). A cross-sectional
study found that serum hs-CRP levels in subjects with either angiographically
proven coronary artery disease or chronic periodontitis were elevated two-fold
compared with those of healthy individuals, whereas in subjects with both diseases
(coronary artery disease plus chronic periodontitis) the levels were elevated threefold (Kumar et al, 2014).
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Bokhari et al. (2012) showed that in coronary heart disease patients with
periodontitis, non-surgical mechanical periodontal therapy significantly reduced
systemic levels of C-reactive protein, fibrinogen and white blood cells. Another
study conducted by Zhou et al. (2013) concluded that non-surgical periodontal
therapy decreased serum TNF-alpha, IL-6 and CRP levels in chronic periodontitis
patients with stable coronary heart disease. Recently, Ertugrul et al. (2017)
demonstrated that the level of systemic markers of atherosclerosis can be changed
significantly in chronic periodontitis patients with concomitant atherosclerosis in
comparison with systemically healthy patients and chronic periodontitis after nonsurgical periodontal treatment. This periodontal treatment modality, also known as
scaling and root planning, is a routine dental procedure that involves removal of
dental plaque and calculus from teeth surfaces including oral hygiene instructions
to maintain oral health.

In this study, we aim to systematically review the literature to assess the quality
of the included studies, and to determine if they provide any evidence on the effect
of scaling and root planing, which is the routine periodontal treatment in
maintaining lower level of serum inflammatory markers in patients with stable
coronary heart disease.

Objectives:
The aim of this study is to conduct a systematic review to investigate the effect
of dental scaling and root planning on reducing the serum levels of inflammatory
markers in patients with stable coronary heart disease.

Materials and Method:

Criteria for considering studies for this review
Type of studies
Studies assessing the effect of non-surgical scaling and root planing on the level
of serum inflammatory markers in patients with stable coronary heart disease will
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be included in the review. Randomized trials that compare the effect of nonsurgical periodontal therapy on serum inflammatory markers in subjects with
coronary heart disease compared to those who have coronary heart disease but
received no treatment or simple oral hygiene measures only, will be eligible for the
inclusion in the systematic review as they represent the most definite way of
determining whether a cause-effect relation exists between treatment and
outcome.

Type of participants
Studies were eligible for the inclusion in this review when they fulfilled the
following criteria:
1. Patients with stable coronary heart disease confirmed by coronary
angiography, and or history of angina or myocardial infarction.
2. Patients with chronic periodontitis with pocket depths of 4 mm or more are
measured at more than one site and have no acute dental infection.
3. Included participants should not have received periodontal treatment within
the past 6 months.
4. Blood samples collected at baseline just before the scaling root planning and
at follow up time ranges from 2 to 6 months.

Type of Intervention
The intervention is non-surgical mechanical periodontal therapy, a procedure
involving supragingival and subgingival scaling and root planning of teeth with
oral hygiene instructions will be compared to no treatment or only simple oral
hygiene instructions.
Type of Outcome measures
▪ Primary outcome:
The main outcome was chosen to be a sensitive indicator in predicting
cardiovascular risk: Reduction in serum concentration of C-reactive protein
▪ Secondary outcomes:
Reduction in serum concentration of other proinflammatory
biomarkers: including IL-6, TNF- and fibrinogen

Exclusion Criteria:
6

▪ Studies considered the use of adjunctive local or systemic antimicrobial
therapy
▪ Studies included smokers, pregnant patients or patients with other severe
systemic conditions that could affect level of serum markers.
▪ Pilot studies
▪ Non-English literature
▪ Animal studies.

Electronic Searches
The following databases were searched with no publication year or publication
status restrictions:
•
•
•

PubMed (to May, 2018), using the strategy in Appendix 1
Scopus (to May, 2018), using the strategy in Appendix 2
Cochrane Central Register of Controlled Trials (CENTRAL) (to May, 2018),
using the search strategy in Appendix 3

Searching other resources
The following trial registers were searched for completed studies:
•
•

U.S. National Institutes of Health Trials Registry (ClinicalTrials.gov)
World Health Organization (WHO) International Trials Registry Platform
(www.who.int/ictrp/en/)

Gray literature was searched using the following resource:
• Google Scholar beta

Search Strategy
To identify studies considered for this review, searches conducted for each
electronic database were modelled on a detailed search strategy developed for
PubMed and modified for each database to accommodate differences in
controlled vocabulary and syntax rules. The search was based on keywords
and “Mesh” terms shown in appendices 1, 2 and 3.
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Selection Process
The titles and abstracts identified through the electronic searches were
screened and then assessed for eligibility criteria by full text as per PRISMA.
RefWorks reference management software was used to merge search terms
and deduplicate from the different databases. Studies not meeting the inclusion
criteria were excluded and the reason for their exclusion is outlined (Table 2).
The screening and selection process is demonstrated in a PRISMA flow
diagram (Figure 1).

Data collection & management
Data extraction template from Cochrane Consumers and Communication Review
Group for included studies (2015) available at http://cccrg.cochrane.org/authorresources, was used to record characteristics of the included studies in a table
considering the following data (Table 1):
•
•
•
•
•
•

General information (author, year, title, journal, dental procedure)
Trial characteristics (sample size, type of study design, method of
randomization, allocation concealment, blinding)
Type of intervention (number of intervention groups, time between
intervention and blood sampling, frequency)
Characteristics of participants (total number of participants, age, gender,
diagnostic criteria for both CVD and periodontitis)
Type of outcome measures (Outcomes definitions and unit of
measurements, time of collection)
Miscellaneous (conclusion and source of funding/conflict of interest)

Assessment for the Risk of Bias
Two review authors independently assessed the risk of bias of the included
randomized controlled trials using the Cochrane Collaboration tool criteria
outlined in Chapter 8 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins et al, 2011), at http://handbook.cochrane.org.
The following domains were assessed:
•
•
•
•

Sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
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•
•
•

Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other potential sources of bias, such as confounding bias.
The judgements for assessing the risk of bias were categorized as ‘low
risk’, as ‘high risk, or as ‘unclear risk’ and interpreted as follows:
• Low risk of bias: plausible bias unlikely to seriously alter the results if
all domains were at low risk of bias.
• Unclear risk of bias: plausible bias that raises some doubt about the
results if one or more domains were at unclear risk of bias.
• High risk of bias: plausible bias that seriously weakens confidence in
the results if one or more domains were at high risk of bias.

Statistical Analysis
Assessment of heterogeneity
Statistical heterogeneity, which is the percentage of variation across the studies
not due to chance was assessed using the I2 statistics.
•
•
•

25-50% small degree of heterogeneity
50-75% moderate degree of heterogeneity
75-100% large degree of heterogeneity

Figure 1: Study Flow Chart
Records identified through
database searching
PubMed (n= 106)
Scopus (n= 134)
Cochrane Library (n= 113)

Additional records identified through
Other sources
ClinicalTrials.gov (n=1)
Google scholar (n=4)

Records after duplicates removed
(n = 276)

Records screened
(n = 276)
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Records excluded
(n = 240)

Full-text articles assessed
for eligibility
(n = 36) Full text

Studies included in
qualitative synthesis
(n = 4)

Full-text articles excluded, with
reasons
(n = 32)
Pilot: (n= 3)
Case-control: (n=1)
Controlled clinical trial: (n=2)
Mata-analysis: (n=1)
Review: (n=3)
Missing data: (n=1)
Subjects in the control group not
diagnosed with coronary heart
disease: (n=14)
CRP is not an outcome measure: (n=2)
Non-English literature: (n=1)
Irrelevant article: (n=1)
Combing other interventions: (n=3)

Results
A total of 358 studies were identified. Searching in PubMed and Scopus resulted
in 106 and 134 studies, respectively. Searching in Cochrane Central Register of
Controlled Trials resulted in 113 trials. Considering other sources, only 1 eligible
study from clinicalTrials.gov and 4 eligible studies from Google Scholar could be
retrieved. The search of the World Health Organization (WHO) International Trials
Registry Platform resulted did not identify any relevant trial. After deduplications of
the results using RefWorks reference management software, we resulted in 276
studies. Screening by title and abstract resulted in the elimination of most of the
studies that were clearly ineligible. Full text evaluation of the remaining 36 articles
resulted in excluding 32 articles and the identification of 4 eligible studies
assessing the effect of non-surgical periodontal therapy on serum inflammatory
markers in patients with periodontitis and coronary heart disease (Table 1).
Reasons for excluding the 32 articles after full text evaluation are listed in (Table
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2). Refer to ‘Study flow chart’ showing the stages of the screening and the number
of studies filtered at each stage (Figure 1).

Study Characteristics
The four selected studies were randomized controlled trials published in English.
One Study was conducted in Pakistan (Bokhari et al, 2012), One in China (Zhou
et al, 2013), and two in India (Hada et al, 2015; Koppolu et al, 2013). The included
studies involved a total of 502 participants with 307 patients in the intervention
group and 195 in the control group. The mean age ranges from (49.00.6 to
62.119.30) years in the intervention group and from (50.10.9 to 62.4812.24)
years in the control group. In the study conducted by (Bokhari et al, 2012) 64
subjects were dropped out from the trial due to changes in their medical history or
due to personal and logistic reasons. Ten patients out the 64 were exited from the
study because they received percutaneous cardiac intervention (PCI) or other
cardiac intervention. In another study (Hada et al, 2015) twelve patients were
excluded because they were hospitalized for cardiac reasons. Only one patient
was lost from (Koppolu et al, 2013) study and no patient withdrew from the study
by (Zhou et al, 2013). The intervention of the 4 studies was non-surgical scaling
and root planing combining curettes and ultrasonic instruments at baseline with no
adjunctive antimicrobial or laser therapy.
Although the included studies have met all planned inclusion criteria, they
differed in many ways. Number of scaling and root planing sessions varied among
the studies between 2 to 4 sessions in 24 hours to 3 weeks interval. In addition,
the time for sample collections also differs among the trials. Other than baseline
sample collection, one trial (Koppolu et al, 2013) considered re-sampling at 2
months follow up and another trial (Zhou et al, 2013) at 3 months. In the study
done by (Bokhari et al, 2012) blood samples were collected at two intervals, 1
month and 2 months and in (Hada et al, 2015) blood sampling was at three
intervals, 1 month, 3 months and 6 months follow ups. C- reactive protein was
reported in all of the studies, whereas TNF- in 2 studies and IL-6 and Fibrinogen
each in one study. Regarding the diagnostic criteria for stable coronary heart
disease, two studies (Bokhari et al, 2012; Zhou et al, 2013) clearly stated that the
diagnosis of stable CHD has to be proven angiographically. In the other two studies
the criteria were history of cardiovascular event. Moreover, the studies considered
different diagnostic criteria for periodontitis for the inclusion of their participants.
Further details in ‘Characteristics of the included studies’ (Table 1).
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Risk of Bias in Included Studies
Quality assessment of selected studies was performed with the Cochrane
Collaboration tool for assessing risk of bias (Higgins et al, 2011).
Randomization was clearly reported in 2 studies, in which allocation of patients
into intervention and control groups was concealed using sealed envelopes
(Bokhari et al, 2012; Hada et al, 2015). In (Zhou et al, 2013) Patients were given
the option to be in the intervention group or the treatment group, which considered
a high risk of selection bias. The process of randomization and allocation
concealment were not clearly described by (Koppolu et al, 2013).
Due to the nature of the intervention (scaling and root planing) blinding of
patients was not possible in all of the trials. Blinding of outcome assessment was
mentioned by two trials (Bokhari et al, 2012; Hada et al, 2015), but was not clear
for the other two studies (Koppolu et al, 2013; Zhou et al, 2013). All of the studies
demonstrated low risk attrition bias and selective reporting bias (Table 3).

Effect of Intervention

Primary outcome
All included randomized clinical trials have considered C-reactive protein (CRP)
as their primary outcome. At baseline, there was no significant difference found in
the level of (CRP) between the intervention and control groups in three of the
studies (Bokhari et al, 2012; Koppolu et al, 2013; Zhou et al, 2013). One study
noted a statistically significant difference in the level of (CRP) between the
treatment and control groups (intergroup) at baseline (Hada et al, 2015), which
remarkably contributed to heterogeneity among the studies. In addition, C-reactive
protein along with other studies parameters were assessed at baseline before the
intervention and over variable follow up periods of 2 months (Bokhari et al, 2012;
Koppolu et al, 2013), 3 months (Hada et al, 2015; Zhou et al, 2013), and 6 months
(Hada et al, 2015). Heterogeneity was calculated at baseline using the I2 statistics
with 95% confidence interval, I2= 53%, which considered a moderate
heterogeneity. Due to lack of consistency, it was difficult to pool the overall effect
of in one forest plot.
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Three of the four RCTs showed a statistically significant reduction in the level
of (CRP) in the intervention group compared to the control from baseline to follow
up visits which ranged between 2 and 3 months (Bokhari et al, 2012; Koppolu et
al, 2013; Zhou et al, 2013). Hada et al. (2015) observed statistically non-significant
increase in the level of (CRP) in the intervention group compared with statistically
significant increase in the control group at 6 months follow up (Table 4). Mean plot
used to demonstrate IL- (Figure 2).

Figure 2: Mean plot: showing changes in mean differences over
follow-up periods for C-reactive protein (CRP)
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Secondary outcomes
Secondary outcomes of our review include interleukin-6, Tumor necrosis factor-
and Fibrinogen. There were variations between the included trials in considering
the cardiovascular inflammatory risk markers being evaluated in each individual
study. In regards to serum fibrinogen, only one study (Bokhari et al, 2012) have
compared the change in its value between the intervention and the control group
from baseline to 1 month and 2 months intervals. The study showed a significant
reduction in the mean SE between baseline fibrinogen (367.110.4 mg/L) and at
1 month follow up visit (305.38.7 mg/L) and 2 months visit (299.38.0 mg/L) only
for the intervention group with a statistically significant difference (P =0.01) in
comparison with the control group at 2 months follow up (335.911.8 mg/L).
Comparing the change in tumor necrosis factor- (TNF-) level between
intervention and control group was evaluated by two studies (Koppolu et al, 2013;
Zhou et al, 2013). Koppolu et al. (2013) found a statistically significant (P <0.001)
reduction in the mean value of serum (TNF-) in the intervention group from
(22.141.46 to 20.21.61 pg/dl) compared to not statistically significant reduction
in the control group (P >0.05) from (22.851.29 to 22.68 pg/dl) at 2 months follow
up. Comparably, (Zhou et al, 2013) showed a reduction in the mean value of serum
(TNF-) at 3 months follow up from baseline in the intervention group (39.8833.83
pg/ml) to (28.9916.56 pg/ml) which was statistically significant (P =0.048), but not
in the control group (49.6169.60 pg/ml) to (50.6486.33 pg/ml). Concerning
serum interleukin-6 (IL-6), only one of the included trials had evaluated the
reduction in its value from baseline to 3 months follow up visit (Zhou et al, 2013).
The mean value of (IL-6) was statistically significantly reduced in the intervention
group (P =0.049) from (38.6121.87 pg/ml) to (31.4020.32), but not in the control
group, in which the value had increased (39.1224.31 pg/ml) to (42.5623.81
pg/ml).

Discussion

The aim of this study is to conduct a systematic review to investigate the effect
of dental scaling and root planning on reducing the serum levels of inflammatory
markers in patients with stable coronary heart disease. We summarized the current
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literature of randomized clinical trials assessing the effect of routine non-surgical
scaling and root planing on serum C-reactive protein, as the main outcome
measure, fibrinogen, TNF- and interleukin-6 in patients with history of coronary
heart disease and are clinically stable at the time of investigation.
The main limitation of the present systematic review is that the changes in serum
levels of the inflammatory markers were assessed at different follow up (sampling)
periods that ranges between 2 months (Bokhari et al, 2012; Koppolu et al, 2013),
3 months (Hada et al, 2015; Zhou et al, 2013), and 6 months (Hada et al, 2015).
This inconsistency makes it difficult to pool the results and to perform a metaanalysis. Additional limitations of this review include the small number of included
studies and the small sample sizes except for (Bokhari et al, 2012). Moreover,
there were variations in the consideration of the secondary outcome measures
among the trials.
In general, the results of the included randomized clinical trials appear to
support the effectiveness of scaling and root planing in reducing serum levels of
inflammatory markers C-reactive protein, fibrinogen, TNF- and interleukin-6 over
a period of 2-3 months. However, random sequence generation was not clearly
reported in one study (Koppolu et al, 2013) and in another study, the patients were
given the option to be in the intervention group or the treatment group (Zhou et al,
2013). In Hada et al. (2015) study, there was a slight increase in level of CRP over
the follow up period in both the intervention and the control groups, but the increase
in the intervention group was less significant compared to the control group at 6
months. With the limited data on investigating the secondary outcomes, the studies
indicate that scaling and root planing could have a positive effect on serum
inflammatory markers fibrinogen, TNF- and interleukin-6. All the included studies
demonstrated improvement in periodontal parameters along with the reduction in
systemic inflammatory markers.
Chronic periodontitis is caused by bacteria attached to teeth surfaces and is
characterized by gingival erythema, bleeding, loss of tooth surrounding
structures, mobility and eventually tooth loss. It contributes to systemic
inflammation characterized by elevation of acute phase proteins, including
inflammatory cytokines such as interleukin-6, coagulation factors such as
fibrinogen, and CRP (Lockhart et al, 2012). Induction of CRP in hepatocytes in
response to inflammation is mainly regulated by cytokines like interleukin-6,
interleukin-1 (Black et al, 2004), and Tumor necrosis factor- (Ebersole et al,
2000). C-reactive protein has been strongly associated with coronary heart
disease. A meta-analysis found relative risk for incident coronary heart disease
was 1.58 (95% CI, 1.37 to 1.83) for CRP levels > 3.0 mg/L compared with CRP
levels <1.0 mg/L (Buckley et al, 2009). A Framingham Heart Study to assess the
role of CRP on vascular risk, concluded that CRP levels help to estimate risk for
15

initial cardiovascular events and may be used most effectively in persons at
intermediate risk for vascular events (Wilson et al, 2008). The American College
of Cardiology/American Heart Association 2013 guidelines on the assessment of
cardiovascular risk, recommend the use of additional risk markers including hsCRP, when risk-based decisions about initiation of pharmacological therapy are
uncertain, after quantitative risk assessment, with CRP with 2 mg/L support
revising risk assessment (Goff et al, 2013).
Many pharmacological agents have been evaluated to suppress C-reactive
protein. However, they have not been associated with atherosclerotic
cardiovascular disease event reduction, or their predominant cardiovascular
benefits could be attributed to another mechanism of action such as aspirin and
statins (Martinez et al, 2018). Methotrexate suppresses systemic inflammation
including serum CRP was associated with a 21% lower risk for total CVD (n = 10
studies, 95% confidence interval [CI] 0.73 to 0.87, p <0.001) and an 18% lower
risk for myocardial infarction (n = 5, 95% CI 0.71 to 0.96, p = 0.01) in systematic
review and meta-analysis on patients with rheumatoid arthritis, psoriasis, or
polyarthritis (Micha et al, 2011).

With the limitations of the available evidence, it suggests that routine nonsurgical periodontal therapy, which mainly consists of scaling and root planing of
the dentition, may progressively reduce level of CRP and other serum
inflammatory markers between periodontal maintenance visits in patients with
stable coronary heart disease. Scaling and root planing considered a safe antiinflammatory intervention (Achtari et al, 2012), in which the majority of cases do
not require antimicrobial pharmacological agents and thus reducing the potential
for adverse events and offering new treatment options for patients with
contraindications for anti-inflammatory medications such as statins or aspirin
(Demmer et al, 2013).
More prospective randomized clinical trials of longer follow up durations are
required to sufficiently assess whether routine periodontal treatment with the
maintenance of good oral hygiene would add a value in the prevention secondary
vascular events by reducing systemic inflammatory burden in patient with stable
coronary heart disease. However, it might be unethical to rely on RCTs to assess
the effect of scaling and root planing over a long follow up duration, > 6 months,
in which the participants in the control group need to be precluded from receiving
prophylactic scaling and root planing for the maintenance of their oral health.
Instead, well-designed observational studies, such as cohort or case-control designs
may add a value in evaluating the effect of scaling and root planing on cardiovascular
risk. Interpretation of the results obtained from both RCTs and observational
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studies can help understand the efficacy/effectiveness and safety of a
therapeutic option (Faraoni & Schaefer, 2016). Most of the observational studies
were conducted to correlate coronary heart disease with periodontal disease, but
not periodontal interventions. A retrospective cohort study used insurance
claimed data from 338,891 individuals followed up from 2005 to 2009,
investigated the effect of periodontal treatment on medical costs and
hospitalization among individuals with type 2 diabetes, coronary heart disease,
cerebral vascular disease, rheumatoid arthritis, and pregnancy. They found that
patients with diabetes or cardiovascular disease showed a significant 20%-40%
reductions in both outcomes relative to controls, which appeared to persist up to
3 years after initial periodontal therapy (Jeffcoat et al,2014).
Furthermore, testing biomarkers such as total cholesterol, low-density
lipoprotein (LDL) cholesterol, high-density lipoprotein cholesterol, triglycerides,
serum creatinine (estimated glomerular filtration), and fasting blood glucose for
the evaluation of modifiable risk factors for the progression of atherosclerosis is
also fundamental to direct secondary preventive measures in patients with stable
coronary heart disease (Morrow et al, 2010).

Conclusion
There is a low evidence from the current literature supporting the effect of
scaling and root planing in reducing systemic inflammatory markers including Creactive protein, tumor necrosis factor- (TNF-), interleukin-6 (IL-6), and
fibrinogen in patients with coronary heart disease. Future research should
include observational studies to assess the effect of scaling and root planing in
reducing the inflammatory burden in this targeted population and the risk of
secondary cardiovascular event.
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Table 1: Characteristics of Included studies
Author(s)
, year

Study
desig
n

Sample
size

Periodontal
therapy

Bokhari
et al,
2013

RCT

n = 317

Nonsurgical
periodontal
therapy
included
supra- and
sub-gingival
scaling and
root
planning
and oral
hygiene
instructions
in 2 to 4
visits within
10 days

Interventio
n group (n
=212)
Control
group (n
=105)

Diagnostic
Criteria for
Coronary heart
disease
Stable
angiographicall
y proven CHD;
defined having
> 50% stenosis
of >1 coronary
artery
documented
by
angiography

Diagnostic
Criteria for
Periodontal
disease
 4 teeth
with 1 site
with
periodontal
probing
depth
(PPD)  4
mm and
clinical
attachment
level (CAL)
 3 mm at
same site,
bleeding
on Probing
(BOP)
>20%

Intervals
between
blood
samples
Blood
samples
collected
between
8 a.m.-12
p.m. (to
control
diurnal
variations
) at
baseline,
at 1
month
and 2
months
follow up
visits.

Outcome
measures

Conclusion

Primary
outcome:

CRP baseline (mg/L):
Control: 4.20.3
Intervention: 4.40.2

Change in
CRP level
at 1 and 2
months
after
completion
of SRP

Secondar
y
outcome:
Fibrinogen
and WBCs
level at 2
months
after
completion
of SRP

CRP at 1 month
(mg/L):
Control: 4.10.3
Intervention: 3.40.2
CRP at 2 months
(mg/L):
Control: 4.10.3
Intervention: 3.10.2
Fibrinogen baseline
(mg/L):
Control: 339.610.5
Intervention:367.110.
4
Fibrinogen at 1
month (mg/L):
Control: 325.59.6
Intervention:305.3.38
.7
Fibrinogen at 2
months (mg/L):
Control: 335.911.8
Intervention:299.3
8.0

Hada et
al, 2015

RCT

n = 70
Interventio
n group (n
=35)

Nonsurgical
periodontal
therapy
included
scaling and
root planing
and oral

Stable CHD,
including
stable angina,
STEMI and
non-STEMI
and in which
symptoms
remained
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Mild to
moderate
chronic
periodontiti
s with  4
teeth with
clinical
attachment

Blood
samples
collected
at
baseline,
and at 1,
3, and 6
months

Primary
outcome:
Change in
CRP level
at 1, 3, and
6 months
after
completion
of SRP

CRP baseline (mg/L):
Control: 3.622.31
Intervention:
5.102.00
CRP at 1 month
(mg/L):
Control: 4.312.43
Intervention:
6.211.92

Control
group (n
=35)

Koppolu
et al,
2013

RCT

n = 40
Interventio
n group (n
=20)
Control
group (n
=20)

hygiene
instructions
in 2 sittings
with 24
hours
interval

stable for at
least 60 days
and no
evidence of
recent
myocardial
damage

loss (CAL)
 4 mm at
 1 site

Nonsurgical
periodontal
therapy
included
scaling and
root planing
performed
once a
week for 3
weeks

History of
myocardial
infarction

Probing
depth of 
5 mm
evaluated
at 4 sites
per tooth

follow up
visits
Secondar
y
outcome:
Changes in
lipid profile,
WBC
profile, and
systolic BP
at 1, 3, and
6 months
after
completion
of SRP

Blood
samples
collected
at
baseline
and at 8
weeks
follow up
visit

Primary
outcome:
Change in
CRP and
TNF-alpha
level at 8
weeks

CRP at 3 months
(mg/L):
Control: 4.091.82
Intervention:
6.223.64
CRP at 6 months
(mg/L):
Control: 4.942.04
Intervention:
6.307.53

CRP baseline (g/dl):
Control: 0.470.11
Intervention:
0.450.12
CRP at week 8
(g/dl):
Control: 0.450.14
Intervention:
0.290.12
TNF- at baseline
(pg/dl):
Control: 22.851.29
Intervention:
22.141.46
TNF- at week 8
(pg/dl):
Control: 22.681.23
Intervention:
20.201.61

Zhou et
al, 2013

RCT

n = 75
Interventio
n group (n
=40)
Control
group (n
=35)

Nonsurgical
periodontal
therapy
included
supragingiv
al scaling
and four
sessions of
quadrant
root
debridement
with oral
hygiene
instructions

Stable CHD
with one of the
following
criteria:
previous
history of
myocardial
infarction, or
angioplasty
surgery more
than 6 months
previously, or
proven
coronary or left
main stem
vessel
obstruction by
more than 50%
by
angiography
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More than
30% of
teeth with
probing
depth (PD)
 4 mm
and clinical
attachment
loss (CAL)
 3 mm,
and with
alveolar
bone loss
>30% of
the root
length
shown on
Panoramic
radiograph.
In addition,
at least 2
teeth
showed
both (PD)
 5 mm
and (CAL)
 3 mm
distributed
in different
quadrants

Blood
samples
collected
between
8 a.m.10 a.m.
at
baseline
and at 3
months
follow up
visit

Primary
outcome:
Change in
CRP, TNFalpha and
IL-6 serum
level at 3
months

Secondar
y
outcomes
:
Change in
WBC
counts,
total
cholesterol,
triglyceride,
HDL, LDL
and blood
glucose
level at 3
months

CRP baseline (mg/L):
Control: 2.963.55
Intervention:
2.613.16
CRP 3 months
(mg/L):
Control: 2.943.62
Intervention:
2.062.54
TNF- at baseline
(pg/dl):
Control: 49.6169.60
Intervention:
39.8833.83
TNF- at 3 months
(pg/dl):
Control: 50.6486.33
Intervention:
28.9916.56
IL-6 at baseline
(pg/dl):
Control: 39.1224.31
Intervention:
38.6121.87
IL-6 at 3 months
(pg/dl):
Control: 42.5623.81
Intervention:
31.4020.32

Table 2: Characteristic of Excluded Studies
Study
Reason for exclusion
Arrol et al. (2015). Relationship of root canal Root canal therapy is the only dental
treatment to C-reactive protein as an
intervention
inflammatory marker for cardiovascular
disease
Arvanitidis et al. (2017) Reduced platelet
hyper-reactivity and platelet-leukocyte
aggregation after periodontal therapy

Controlled clinical trial and different
outcome measures for the evaluation of
cardiovascular risk

Beck et al. (2008). The Periodontitis and
Vascular Events (PAVE) pilot study:
adverse events

Pilot Study

Bresolin et al. (2013). Lipid profiles and
inflammatory markers after periodontal
treatment in children with congenital heart
disease and at risk for atherosclerosis

Pediatric Population with variations in
the diagnosis of congenital heart
diseases

Caula et al. (2014). The effect of periodontal
therapy on cardiovascular risk markers: A 6month randomized clinical trial

Subjects with periodontits were not
diagnosed with coronary heart disease

D’Aiuto et al. (2006). Periodontal infections
cause changes in traditional and novel
cardiovascular risk factors: results from a
randomized controlled clinical trial.

Subjects with periodontitis were
systemically healthy

D’Aiuto et al. (2005). Short-term effects of
intensive periodontal therapy on serum
inflammatory markers and cholesterol

Subjects with periodontitis were
systemically healthy

D’Aiuto et al. (2004). Periodontitis and
atherogenesis: Causal association or simple
coincidence

Pilot Study
Subjects with periodontitis were
systemically healthy
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D’Aiuto et al. (2007). Acute effects of
periodontal therapy on bio-markers of
vascular health

Subjects with periodontitis were
systemically healthy
Follow and up to 30 days

Gao et al. (2016). Effects of essential
periodontal treatment on serum level of
sCD40L and periodontal clinical parameters
in patients with moderate to severe
periodontitis at high risk of stroke

Different outcome measures
Non- English literature (Chinese)

Ide et al. (2003). Effect of treatment of
chronic periodontitis on levels of serum
markers of acute-phase inflammatory and
vascular responses

Subjects with periodontitis not coronary
heart disease

Javed et al. (2016). Effect of Nd:YAG laser- Pilot study
assisted non-surgical periodontal therapy on Intervention is laser assisted nonclinical periodontal and serum biomarkers in surgical periodontal therapy
patients with and without coronary artery
disease: A short-term pilot study
Lapez et al. (2012). Effects of periodontal
therapy on systemic markers of
inflammation in patients with metabolic
syndrome: A controlled clinical trial

Subjects with metabolic syndrome
Controlled clinical trial

Leite et al. (2014). Effects of periodontal
therapy on C-reactive protein and HDL in
serum of subjects with periodontitis

Subjects with periodontitis were
systemically healthy

Li et al. (2011). Effect of periodontal
treatment on circulating CD34 + cells and
peripheral vascular endothelial function: A
randomized controlled trial

Subjects with periodontitis were
systemically healthy
Different outcome measures

Lobo et al. (2016). Treating Periodontal
Disease in Patients With ST-Elevation
Myocardial Infarction: A Randomized
Clinical Trial

Missing Data

Lowe (2004) Dental Disease, Coronary
Heart Disease and Stroke, and
Inflammatory Markers: What Are the
Associations, and What Do They Mean?

Review article
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Merchant et al. (2017). Evaluating
Periodontal Treatment to Prevent
Cardiovascular Disease: challenges and
Possible Solutions

Review article

Meuman et al. (2004). Oral health,
atherosclerosis, and cardiovascular disease

Review article

Monteiro et al. (2012). Measurement of the
nonlinear optical response of low-density
lipoprotein solutions from patients with
periodontitis before and after periodontal
treatment: evaluation of cardiovascular risk
markers

Study excluded patients with history of
cardiovascular disease

Payne et al. (2011). The effect of
subantimicrobial-dose-doxycycline
periodontal therapy on serum biomarkers of
systemic inflammation: a randomized,
double-masked, placebo-controlled clinical
trial

Periodontal therapy included use of
doxycycline

Ramarez et al. (2014). Biomarkers of
cardiovascular disease are increased in
untreated chronic periodontitis: A case
control study

Case control study

Renvert et al. (2009). Short-term effects of
an anti-inflammatory treatment on clinical
parameters and serum levels of C-reactive
protein and proinflammatory cytokines in
subjects with periodontitis

Intervention included a combination of
dipyridamole and prednisolone (CRx102)

Sharma et al. (2014). A study of C-reactive
protein, lipid metabolism and peripheral
blood to identify a link between periodontitis
and cardiovascular disease

Subjects with periodontitis were
systemically healthy

Skilton et al. (2011). The effect of a
periodontal intervention on cardiovascular
risk markers in Indigenous Australians with
periodontal disease: The PerioCardio study

Study excluded patients with history of
cardiovascular disease
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Seymour et al. (1998). Is there a link
between periodontal disease and coronary
heart disease?

Meta-analysis

Tuter et al. (2007). Effects of scaling and
root planing and sub-antimicrobial dose
doxycycline on oral and systemic
biomarkers of disease in patients with both
chronic periodontitis and coronary artery
disease

Both intervention and control groups
received periodontal therapy with/or
without doxycycline respectively

Taylor et al. (2010). The effect of initial
treatment of periodontitis on systemic
markers of inflammation and cardiovascular
risk: A randomized controlled trial

Participants not diagnosed with coronary
heart disease

Thaker et al. (2010). Evaluation of the Creactive protein serum levels in periodontitis
patients with or without atherosclerosis

Case control study

Tonetti et al. (2007). Treatment of
periodontitis and endothelial function

Study excluded patients with history of
cardiovascular disease

Tonregeani et al. (2016). Evaluation of
periodontitis treatment effects on carotid
intima-media thickness and expression of
laboratory markers related to
atherosclerosis

Different outcome measures

Vidal et al. (2009). Periodontal therapy
reduces plasma levels of interleukin-6, Creactive protein, and fibrinogen in patients
with severe periodontitis and refractory
arterial hypertension

Participants not diagnosed with coronary
heart disease
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Table 3: Risk of Bias Assessment
Study

Random
sequence
generation

Allocation
concealment

Blinding of
participants
and
personnel

Bokhari et
al , 2013

Hada et al,
2015

Koppolu et
al, 2013

Zhou et al,
2013
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Blinding of
outcome
assessment

Incomplete
outcome
data

Selective
reporting

Key:

Low risk

High risk

unclear

Standard Deviation: *, Standard Error: ^

Appendices:
Appendix 1:
PubMed=106: ((("Cardiovascular Diseases"[Mesh] OR Cardiovascular Diseases OR
Cardiovascular Disease OR Cardiovascular OR arteriosclerosis OR atherosclerosis OR
"Atherosclerosis"[Mesh] OR "Arteriosclerosis"[Mesh] OR "Myocardial Ischemia"[Mesh]
OR "Acute Coronary Syndrome"[Mesh] OR Myocardial Ischemia OR ischemic heart
disease OR ischemic heart diseases OR myocardial infarction OR myocardial infarctions
OR "Myocardial Infarction"[Mesh] OR Myocardial Infarct OR coronary diseases OR
coronary disease OR coronary heart diseases OR coronary heart disease OR "Coronary
Disease"[Mesh])) AND (((alveolar bone OR "Alveolar Bone Loss"[Mesh] OR "Bone

Table 4: Changes in CRP level over follow up periods
Study

Sample Size

CRP at Baseline

CRP at 1 month

CRP at 2 months

Bokhari et al,
2013

Control
group
(n= 85)
Intervention
(n= 161)

Control:
(4.2 0.3 mg/L)^
(4.2 2.8 mg/L)*
Intervention:
(4.40.2 mg/L)^
(4.4 2.5 mg/L)*

Control:
(4.10.3 mg/L)^
(4.1 2.8 mg/L)*
Intervention:
(3.40.2 mg/L)^
(3.4 2.5 mg/L)*

Control:
(4.10.3 mg/L)^
(4.1 2.8 mg/L)*
Intervention:
(3.10.2 mg/L)^
(3.1 2.5 mg/L)*

Control:
(3.622.31 mg/L)*
Intervention:
(5.102.00 mg/L)*

Control:
(4.312.43
mg/L)*
Intervention:
(6.211.92
mg/L)*

Total n= 246
Hada et al,
2015

Koppolu et al,
2013

Zhou et al,
2013

Control
group
(n= 25)
Intervention
(n= 30)
Total n= 55
Control
group
(n= 19)
Intervention
(n= 20)

Control:
(0.470.11 g/dl)*
Intervention:
(0.450.12 g/dl)*

Total n= 39
Control
group
(n= 35)
Intervention
(n= 40)

Control:
(2.963.55 mg/L)*
Intervention:
(2.613.16 mg/L)*

CRP at 3 months

CRP at 6 months

Not Applicable

Not Applicable

Not Applicable

Control:
(4.091.82 mg/L)*
Intervention:
(6.223.64 mg/L)*

Control:
(4.942.04 mg/L)*
Intervention:
(6.307.53 mg/L)*

Not Applicable

Control:
(0.450.14 g/dl)*
Intervention:
(0.290.12 g/dl)*

Not Applicable

Not Applicable

Not Applicable

Not Applicable

Control:
(2.943.62 mg/L)*
Intervention:
(2.062.54 mg/L)*

Not Applicable

Total n= 75

Resorption"[Mesh] OR Alveolar bone loss OR "bone loss" OR periodontal attachment
loss OR "Periodontal Attachment Loss"[Mesh] OR periodontitis OR periodontal disease
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OR periodontal diseases OR "Periodontal Diseases"[Mesh] OR "Gingival
Diseases"[Mesh] OR chronic periodontitis OR Gingival disease OR Gingival diseases OR
"Chronic Periodontitis"[Mesh] OR periodontal index OR "Periodontal Index"[Mesh] OR
"Gingival Pocket"[Mesh] OR "Periodontal Pocket"[Mesh])) OR (periodontal therapy OR
periodontal treatment OR periodontal treatments OR periodontal index OR "Periodontal
Index"[Mesh] OR dental prophylaxis OR "Dental Prophylaxis"[Mesh] OR periodontal
debridement OR subgingival debridement OR subgingival curettage OR "Periodontal
Debridement"[Mesh] OR "Subgingival Curettage"[Mesh] OR scaling OR "Dental
Scaling"[Mesh] OR root planing OR "Root Planing"[Mesh] OR scaling root planing OR
subgingival scaling OR supragingival scaling OR non-surgical dental OR non-surgical
periodontal OR non-surgical dental therapy OR non-surgical periodontal therapy OR nonsurgical periodontal treatment))) AND (Biomarkers OR "Biomarkers"[Mesh] OR Biomarker OR inflammatory markers OR serum markers OR biological markers OR plasma
level OR inflammatory mediators OR Proinflammatory mediators OR Pro-inflammatory
mediators OR Pro-inflammatory mediator OR Proinflammatory mediator OR inflammatory
mediator OR inflammatory marker OR biomarker OR serum marker OR interleukin OR
interleukins OR "Interleukins"[Mesh] OR IL6 OR IL-6 OR interleukin 6 OR "Interleukin6"[Mesh] OR "IL6 protein, human" [Supplementary Concept] OR Tumor Necrosis Factoralpha OR Tumour Necrosis Factor-alpha OR tumor necrosis-alpha OR tumor necrosis
factor-α OR “Tumor Necrosis Factor-alpha"[Mesh] OR "TNF protein, human"
[Supplementary Concept] OR tnf alpha OR tnf-alpha OR tnf-α OR c-reactive protein OR
"C-Reactive Protein"[Mesh] OR C-reactive proteins OR cytokines OR cytokine OR
"Cytokines"[Mesh] OR fibrinogen OR "Fibrinogen"[Mesh] OR fibrinogens OR "Gingival
Crevicular Fluid/chemistry"[Mesh] OR "Gingiva/immunology"[Mesh]) Filters: Randomized
Controlled Trial; Clinical Trial

Appendix 2:
Scopus=134: ( TITLE-ABS-KEY ( cardiovascular W/2 disease* ) OR TITLE-ABS-KEY
( cardiovascular ) OR TITLE-ABS-KEY ( arteriosclerosis ) OR TITLE-ABS-KEY (
atherosclerosis ) OR TITLE-ABS-KEY ( acute PRE/0 coronary PRE/0 syndrome*
) OR TITLE-ABS-KEY ( {Myocardial Ischemia} ) OR TITLE-ABS-KEY (
ischemic
PRE/0
heart
PRE/0
disease*
)
OR
TITLE-ABS-KEY (
myocardial PRE/0 infarct* ) OR TITLE-ABS-KEY ( coronary W/2 disease* ) ) AND (
TITLE-ABS-KEY ( {alveolar bone} ) OR TITLE-ABS-KEY ( {Alveolar Bone Loss}
) OR TITLE-ABS-KEY ( bone W/2 resorption ) OR TITLE-ABS-KEY ( {Periodontal
attachment loss} ) OR TITLE-ABS-KEY ( periodontitis ) OR TITLE-ABS-KEY (
periodont* W/2 disease* ) OR TITLE-ABS-KEY ( {chronic periodontitis} ) OR TITLEABS-KEY ( gingiva* W/2 disease* ) OR TITLE-ABS-KEY ( periodontal PRE/0 ind*
) OR TITLE-ABS-KEY ( gingival PRE/0 pocket* ) OR TITLE-ABS-KEY (
periodontal PRE/0 pocket* ) ) OR ( TITLE-ABS-KEY ( periodont* W/2 therapy
) OR TITLE-ABS-KEY ( periodont* W/2 treatment* ) OR TITLE-ABS-KEY (
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periodontal PRE/0 ind* ) OR TITLE-ABS-KEY ( {dental prophylaxis} ) OR TITLE-ABSKEY
(
periodont*
W/2
debridement*
)
OR
TITLE-ABS-KEY
(
subgingival
PRE/0
debridement*
)
OR
TITLE-ABS-KEY
(
subgingival PRE/0 curettage ) OR TITLE-ABS-KEY ( scaling ) OR TITLE-ABS-KEY (
root PRE/0 planing ) OR TITLE-ABS-KEY ( scaling PRE/0 root PRE/0 planing
) OR TITLE-ABS-KEY ( subgingival PRE/0 scaling ) OR TITLE-ABS-KEY (
supragingival PRE/0 scaling ) OR TITLE-ABS-KEY ( non-surgical W/2 dental
) OR TITLE-ABS-KEY ( non-surgical W/2 periodont* ) OR TITLE-ABS-KEY ( nonsurgical
AND dental
AND therapy )
OR
TITLE-ABS-KEY ( nonsurgical PRE/0 periodontal PRE/0 therapy ) OR TITLE-ABS-KEY ( nonsurgical PRE/0 periodontal PRE/0 treatment ) ) AND ( TITLE-ABS-KEY ( biomarkers
) OR TITLE-ABS-KEY ( bio-marker ) OR TITLE-ABS-KEY ( inflammat* W/2 marker*
) OR TITLE-ABS-KEY ( serum W/2 marker* ) OR TITLE-ABS-KEY (
biological PRE/0 marker* ) OR TITLE-ABS-KEY ( {plasma level} ) OR TITLE-ABSKEY ( inflammat* W/2 mediator* ) OR TITLE-ABS-KEY ( proinflammatory AND
mediator* ) OR TITLE-ABS-KEY ( pro-inflammatory AND mediator* ) OR TITLE-ABSKEY ( interleukin ) OR TITLE-ABS-KEY ( interleukins ) OR TITLE-ABS-KEY ( il6
) OR TITLE-ABS-KEY ( il-6 ) OR TITLE-ABS-KEY ( interleukin 6 ) OR TITLE-ABSKEY ( tumor AND necrosis AND factor-alpha ) OR TITLE-ABS-KEY ( tumour AND
necrosis AND factor-alpha ) OR TITLE-ABS-KEY ( tumor AND necrosis AND factor-α
) OR TITLE-ABS-KEY ( tnf PRE/0 alpha ) OR TITLE-ABS-KEY ( tnf-α ) OR TITLEABS-KEY ( c-reactive AND protein* ) OR TITLE-ABS-KEY ( cytokine* ) OR TITLEABS-KEY ( fibrinogen* ) OR TITLE-ABS-KEY ( gingiva* W/2 immunology ) ) AND (
LIMIT-TO ( EXACTKEYWORD , "Clinical Trial" ) OR LIMIT-TO ( EXACTKEYWORD
, "Randomized Controlled Trial" ) )

Appendix 3:
Cochrane Library=269 (113 Trials): ([mh "Cardiovascular Diseases"] OR Cardiovascular
Diseases OR Cardiovascular Disease OR Cardiovascular OR arteriosclerosis OR
atherosclerosis OR [mh "Atherosclerosis"] OR [mh "Arteriosclerosis"] OR [mh "Myocardial
Ischemia"] OR [mh "Acute Coronary Syndrome"] OR Myocardial Ischemia OR ischemic
heart disease OR ischemic heart diseases OR myocardial infarction OR myocardial
infarctions OR [mh "Myocardial Infarction"] OR Myocardial Infarct OR coronary diseases
OR coronary disease OR coronary heart diseases OR coronary heart disease OR [mh
"Coronary Disease"]) AND (alveolar bone OR [mh "Alveolar Bone Loss"] OR [mh "Bone
Resorption"] OR Alveolar bone loss OR "bone loss" OR periodontal attachment loss OR
[mh "Periodontal Attachment Loss"] OR periodontitis OR periodontal disease OR
periodontal diseases OR [mh "Periodontal Diseases"] OR [mh "Gingival Diseases"] OR
chronic periodontitis OR Gingival disease OR Gingival diseases OR [mh "Chronic
Periodontitis"] OR periodontal index OR [mh "Periodontal Index"] OR [mh "Gingival
Pocket"] OR [mh "Periodontal Pocket"] OR periodontal therapy OR periodontal treatment
OR periodontal treatments OR periodontal index OR [mh "Periodontal Index"] OR dental
prophylaxis OR [mh "Dental Prophylaxis"] OR periodontal debridement OR subgingival
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debridement OR subgingival curettage OR [mh "Periodontal Debridement"] OR [mh
"Subgingival Curettage"] OR scaling OR [mh "Dental Scaling"] OR root planing OR [mh
"Root Planing"] OR scaling root planing OR subgingival scaling OR supragingival scaling
OR non-surgical dental OR non-surgical periodontal OR non-surgical dental therapy OR
non-surgical periodontal therapy OR non-surgical periodontal treatment) AND
(Biomarkers OR [mh "Biomarkers"] OR Bio-marker OR inflammatory markers OR serum
markers OR biological markers OR plasma level OR inflammatory mediators OR
Proinflammatory mediators OR Pro-inflammatory mediators OR Pro-inflammatory
mediator OR Proinflammatory mediator OR inflammatory mediator OR inflammatory
marker OR biomarker OR serum marker OR interleukin OR interleukins OR [mh
"Interleukins"] OR IL6 OR IL-6 OR interleukin 6 OR [mh "Interleukin-6"] OR [mh"IL6
protein, human"] OR Tumor Necrosis Factor-alpha OR Tumour Necrosis Factor-alpha
OR tumor necrosis-alpha OR tumor necrosis factor-α OR [mh "Tumor Necrosis Factoralpha"] OR [mh "TNF protein, human"] OR tnf alpha OR tnf-alpha OR tnf-α OR c-reactive
protein OR [mh "C-Reactive Protein"] OR C-reactive proteins OR cytokines OR cytokine
OR [mh "Cytokines"] OR fibrinogen OR [mh "Fibrinogen"] OR fibrinogens OR [mh
"Gingival Crevicular Fluid"/CH] OR [mh "Gingiva"/IM])
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